Insider Selling: Stoke Therapeutics (NASDAQ:STOK) Insider Sells 2,006 Shares of Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) insider Barry Ticho sold 2,006 shares of the business's stock in a transaction on Tuesday, December 2nd. The stock was sold at an average price of $29.78, for a total transaction of $59,738.68. Following the completion of the sale, the insider directly owned 17,170 shares in the company, valued at approximately $511,322.60. This represents a 10.46% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Barry Ticho also recently made the following trade(s):

• On Wednesday, December 3rd, Barry Ticho sold 2,014 shares of Stoke Therapeutics stock. The shares were sold at an average price of $30.65, for a total transaction of $61,729.10.
• On Monday, November 3rd, Barry Ticho sold 5,931 shares of Stoke Therapeutics stock. The stock was sold at an average price of $25.72, for a total transaction of $152,545.32.

Stoke Therapeutics Stock Up 3.9%

NASDAQ:STOK traded up $1.15 on Wednesday, hitting $30.96. The stock had a trading volume of 665,349 shares, compared to its average volume of 1,025,254. The company has a market cap of $1.77 billion, a PE ratio of 46.21 and a beta of 1.14. Stoke Therapeutics, Inc. has a 52 week low of $5.35 and a 52 week high of $38.69. The business's fifty day moving average is $28.58 and its 200 day moving average is $19.53.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last announced its earnings results on Tuesday, November 4th. The company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.54) by ($0.11). Stoke Therapeutics had a net margin of 19.73% and a return on equity of 13.28%. The firm had revenue of $10.63 million during the quarter, compared to analysts' expectations of $6.06 million. Equities analysts predict that Stoke Therapeutics, Inc. will post -2.01 earnings per share for the current fiscal year.

Institutional Trading of Stoke Therapeutics

A number of hedge funds have recently bought and sold shares of the stock. CANADA LIFE ASSURANCE Co increased its stake in Stoke Therapeutics by 12.3% during the 3rd quarter. CANADA LIFE ASSURANCE Co now owns 11,978 shares of the company's stock valued at $296,000 after purchasing an additional 1,313 shares in the last quarter. Polar Capital Holdings Plc lifted its position in shares of Stoke Therapeutics by 49.8% in the third quarter. Polar Capital Holdings Plc now owns 1,323,470 shares of the company's stock valued at $31,102,000 after acquiring an additional 439,824 shares in the last quarter. Parkman Healthcare Partners LLC acquired a new position in Stoke Therapeutics in the 3rd quarter valued at about $5,875,000. Nomura Holdings Inc. acquired a new stake in shares of Stoke Therapeutics during the third quarter valued at about $1,908,000. Finally, Millennium Management LLC raised its position in Stoke Therapeutics by 199.3% in the third quarter. Millennium Management LLC now owns 61,048 shares of the company's stock valued at $1,435,000 after purchasing an additional 40,652 shares during the period.

Analyst Ratings Changes

Several research analysts have recently commented on the company. Weiss Ratings reissued a "hold (c)" rating on shares of Stoke Therapeutics in a report on Monday. Wedbush raised their price target on Stoke Therapeutics from $22.00 to $32.00 and gave the company an "outperform" rating in a research report on Wednesday, November 5th. BTIG Research restated a "buy" rating and set a $39.00 price target on shares of Stoke Therapeutics in a research report on Wednesday, November 5th. JPMorgan Chase & Co. upped their price objective on shares of Stoke Therapeutics from $15.00 to $25.00 and gave the stock a "neutral" rating in a report on Monday, November 3rd. Finally, Needham & Company LLC increased their target price on Stoke Therapeutics from $22.00 to $35.00 and gave the stock a "buy" rating in a research report on Friday, October 10th. Two equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $31.00.

Get Our Latest Research Report on Stoke Therapeutics

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.

Featured Articles

• Five stocks we like better than Stoke Therapeutics
• 3 Warren Buffett Stocks to Buy Now
• 3 Stocks Poised to Benefit From Google’s AI Breakthough
• The Risks of Owning Bonds
• Beyond NVIDIA: 5 Semiconductor Stocks Set to Dominate 2026
• What Are Dividend Challengers?
• 3 Stocks You’ll Wish You Bought Before 2026

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Stoke Therapeutics Right Now?

Before you consider Stoke Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stoke Therapeutics wasn't on the list.

While Stoke Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here